BALA CYNWYD, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
MoneyLion Inc. (NYSE - ML)
Under the terms of the agreement, MoneyLion will be acquired by Gen Digital Inc. (Nasdaq - GEN) for $82.00 per share in cash payable at closing, representing a cash value of approximately $1 billion. The investigation concerns whether the MoneyLion Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal offers fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/moneylion-inc-nyse-ml/.
Marinus Pharmaceuticals, Inc. (Nasdaq - MRNS)
Under the terms of the agreement, Marinus will be acquired by Immedica Pharma AB (“Immedica”) for $0.55 per share in cash. The investigation concerns whether the Marinus Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal offers fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/marinus-pharmaceuticals-inc-nasdaq-mrns/.
Better Choice Inc. (NYSE American - BTTR)
Under the terms of the Merger Agreement, Better Choice will merge with SRx Health Solutions Inc. (“SRx Health”). On closing, securityholders of SRx Health will own approximately 85% of the combined company and securityholders of Better Choice will own approximately 15% of the combined company, on a fully diluted basis.The investigation concerns whether the Better Choice Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to Company shareholders in the combined company.
Additional information can be found at https://www.brodskysmith.com/cases/better-choice-inc-nyse-american-bttr/.
NeueHealth, Inc. (NYSE - NEUE)
Under the terms of the agreement, NeueHealth will be acquired by an affiliate of New Enterprise Associates (“NEA”) for $7.33 per share in an all-cash transaction valued at approximately $1.3 billion on an enterprise basis. The investigation concerns whether the NeueHealth Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal offers fair value to the Company’s shareholders.
Additional information can be found at https://www.brodskysmith.com/cases/neuehealth-inc-nyse-neue/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
